Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Fig. 2

Dapagliflozin could reduce cholesterol accumulation by promoting cholesterol efflux. (A) The cholesterol test kit showed dapagliflozin could relieve cholesterol accumulation (both total cholesterol and free cholesterol) which was induced by high glucose. (B) Nile red staining showed that high glucose induced lipid accumulation could be relieved by dapagliflozin. (C) WB showed that dapagliflozin could restore the expression of ABCA1 but have no effect on LDLR and HMGCR. (D) schematic diagram showed that the protective mechanism of dapagliflozin on podocyte lipotoxicity was promoting cholesterol efflux. (Data presented are the mean ± S.D.; *P < 0.05 vs. LG, # P < 0.05 vs. HG, n = 3)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us